Cloosterman S G, Hofland I D, Lukassen H G, Wieringa M H, van der Heide S, Brunekreef B, van Schayck C P
Department of General Practice and Social Medicine, Medical Centre Dekkerswald, University of Nijmegen, The Netherlands.
J Allergy Clin Immunol. 1997 Sep;100(3):313-9. doi: 10.1016/s0091-6749(97)70243-4.
Asthma caused by allergy to house dust mite is a growing problem. Patients with allergy who do not have asthma (yet) might develop asthma depending on exposure to precipitating factors.
We sought to determine whether house dust mite avoidance measures have an effect on the development of asthma.
Patients with allergy (n = 29) who had no diagnosis of asthma (FEV1 of 99.1% +/- 10.6% of predicted, peak flow variability of 5.21% +/- 3.41%, reversibility of FEV1 after 400 microg salbutamol of 3.92% +/- 3.75% according to the reference values) were randomly allocated (subjects blinded) to a treatment (n = 16) and a placebo group (n = 13). House dust mite avoidance treatment consisted of applying Acarosan (Allergopharma, J. Ganzer KG, Hamburg, Germany) (the placebo group used water) to the floors (living room, bedroom), and the use of covers for mattresses and bedding that were impermeable to house dust mite (the placebo group used cotton covers for mattresses only). We tested whether the intervention had an effect on peak flow parameters and asthma symptom scores during 6 weeks of treatment.
Significant improvements were seen in the treatment group in symptom scores (Borg score) for disturbed sleep, breathlessness, wheeze, and overall symptom score. Slight but statistically significant improvements in peak flow (morning, evening, and variability) were seen in the treatment group also. No significant changes were seen in the placebo group.
Although this study is not long enough to study the development of asthma, the results indicates that house dust mite avoidance measures had an effect on peak flow parameters and asthma symptoms in patients with allergy but without asthma. These findings might implicate that a shift in developing clinically manifest asthma could be achieved with house dust mite avoidance measures. To give a better answer to whether preventing the development of asthma is possible, larger studies with a longer follow-up period are necessary.
因对屋尘螨过敏引发的哮喘问题日益严重。尚未患哮喘的过敏患者可能会因接触诱发因素而发展为哮喘。
我们试图确定避免接触屋尘螨的措施是否对哮喘的发展有影响。
将未被诊断为哮喘的过敏患者(n = 29)(根据参考值,第1秒用力呼气容积[FEV1]为预测值的99.1%±10.6%,呼气峰值流速变异性为5.21%±3.41%,400微克沙丁胺醇后FEV1的可逆性为3.92%±3.75%)随机分配(受试者 blinded)至治疗组(n = 16)和安慰剂组(n = 13)。避免接触屋尘螨的治疗包括在地板(客厅、卧室)上喷洒Acarosan(Allergopharma,J. Ganzer KG,德国汉堡)(安慰剂组使用水),以及使用对屋尘螨不可渗透的床垫和床上用品罩(安慰剂组仅使用棉质床垫罩)。我们测试了该干预措施在6周治疗期间对呼气峰值流速参数和哮喘症状评分的影响。
治疗组在睡眠障碍、呼吸急促、喘息的症状评分(Borg评分)以及总体症状评分方面有显著改善。治疗组在呼气峰值流速(早晨、晚上及变异性)方面也有轻微但具有统计学意义的改善。安慰剂组未见显著变化。
尽管本研究时间不足够长以研究哮喘的发展,但结果表明避免接触屋尘螨的措施对有过敏但未患哮喘的患者的呼气峰值流速参数和哮喘症状有影响。这些发现可能意味着通过避免接触屋尘螨的措施可改变临床明显哮喘的发展。为了更好地回答是否有可能预防哮喘的发展,需要进行更长随访期的更大规模研究。